MARKET

SMMT

SMMT

Summit Therapeutics Inc
NASDAQ
17.01
-0.22
-1.28%
Pre Market: 17.18 +0.17 +1.00% 07:18 12/18 EST
OPEN
17.65
PREV CLOSE
17.23
HIGH
17.85
LOW
16.99
VOLUME
1
TURNOVER
0
52 WEEK HIGH
36.91
52 WEEK LOW
15.55
MARKET CAP
12.66B
P/E (TTM)
-13.6979
1D
5D
1M
3M
1Y
5Y
1D
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
NASDAQ · 1d ago
Summit Therapeutics Price Target Raised to $18.00/Share From $16.00 by Barclays
Dow Jones · 1d ago
Summit Therapeutics Raised to Equal-Weight From Underweight by Barclays
Dow Jones · 1d ago
Barclays Upgrades Summit Therapeutics to Equal-Weight, Raises Price Target to $18
Benzinga · 1d ago
SUMMIT THERAPEUTICS <SMMT.O>: BARCLAYS RAISES TARGET PRICE TO $18 FROM $16
Reuters · 1d ago
Summit Therapeutics upgraded to Equal Weight from Underweight at Barclays
TipRanks · 1d ago
Summit Therapeutics (SMMT) was upgraded to a Hold Rating at Barclays
TipRanks · 1d ago
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 2d ago
More
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

Webull offers Summit Therapeutics Inc stock information, including NASDAQ: SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SMMT stock methods without spending real money on the virtual paper trading platform.